Henlius, Organon trial drug meets goal of an absence of breast cancer
Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of.
British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an.
Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in.
Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered.
AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.
HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.
HQ Team May 2, 2024: Novartis AG will buy a US-based biotechnology company Mariana Oncology to expand its cancer portfolio for $1 billion..
HQ Team February 8, 2024: Australian scientists may have found a drug to treat triple-negative breast cancer without any toxic effects, according to.
More than 35 million people may have cancer in 2050 — an increase of 77% from 20 million new cases in 2022, according.
HQ Team January 8, 2023: Johnson & Johnson will buy Ambrx Biopharma, Inc., a company developing targeted chemotherapy treatments, for $2 billion in cash..